DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
NK-A 17E-233I: a novel competitive inhibitor of human dihydroorotate dehydrogenase (DHODH) for cancer therapy
Human dihydroorotate dehydrogenase (DHODH) is the rate-limiting enzyme in pyrimidine de novo synthesis and represents a promising target for cancer therapy. However, current inhibitors of DHODH have limited clinical effectiveness and adverse effects. Herein, we report NK-A 17E-233I, a novel small-molecule inhibitor of the human DHODH enzyme, identified through a prospective virtual screening methodology. Molecular docking and biochemical assays show NK-A 17E-233I functions as a pure or partial competitive inhibitor with respect to the natural substrate, dihydroorotate (DHO). It adopts a distinct binding mode from classical inhibitors that target the flavin mononucleotide (FMN) binding cavity of the hydrophobic tunnel. NK-A 17E-233I exhibits selective cytotoxicity in both human cancer cell lines and patient-derived intestinal organoids, inducing DNA damage, S-phase arrest, and cell death. Unlike Brequinar, NK-A 17E-233I preserves mitochondrial respiration via complexes I and II and maintains ATP-linked basal respiration, avoiding the impairment of the electron transport chain (ETC). Our findings imply the aptitude of NK-A 17E-233I as a novel competitive inhibitor of human DHODH, representing a significant advancement in this field since the 1990s., This work was supported by a grant [Plan GenT, CIDEGENT/2021/026] from the CIDEGENT Excellent Research Program of the Valencian regional government, grants [CNS2024-154649 and PID2022-140899NB-I00] awarded by MICIU/AEI/https://doi.org/10.13039/501100011033 and by “ERDF/EU” awarded to MAJ (Juanes Lab). Part of the equipment employed in the current work was funded by Generalitat Valenciana and cofinanced with ERDF funds (OP ERDF of Comunitat Valenciana 2014–2020). A fellowship from "the Generalitat Valenciana, Conselleria de Sanitat—Acciones en materia de recursos humanos para impulsar la investigación y la formación en investigación sanitaria, biomédica y de salud pública para el ejercicio 2024," was awarded to MMA (Juanes Lab). This work was also supported by a grant [PID2022-136791NB-I00] project awarded by MCIN/AEI/https://doi.org/10.13039/501100011033 to PH, EMERGIA 2021 program from the Andalusian Regional Government-Junta de Andalucía (EMC21_00057) to NG-R, and PI21/00554 from the Instituto de Salud Carlos III (cofunded with ERDF) and 202020–30-31 from the Fundació la Marató de TV3 to RM., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-140899NB-I00
,
AEI PID2022-136791NB-I00
DOI: http://hdl.handle.net/10261/414832, https://api.elsevier.com/content/abstract/scopus_id/105019114156
HANDLE: http://hdl.handle.net/10261/414832, https://api.elsevier.com/content/abstract/scopus_id/105019114156